Executive Director, HIV Clinical Development
Gilead Sciences, Inc.
Moupali Das, MD, MPH, is an Executive Director, HIV Clinical Development, in the Virology Therapeutic Area at Gilead Sciences, where she leads the PrEP clinical drug development program, including evaluating the safety and efficacy of lenacapavir, a novel long-acting, twice yearly, subcutaneous injection for HIV prevention as well as expanding the populations who can benefit from F/TDF and F/TAF for PrEP. During the COVID19 pandemic she assisted her colleagues in the remdesivir program, leading the evaluation of remdesivir use in pregnant women and children from the compassionate use program.
After completing her undergraduate degree in Biochemical Sciences at Harvard College, medical school and internal medicine residency training at Columbia University and New York Presbyterian Hospital, she came to University of California, San Francisco (UCSF) for fellowship training in Infectious Diseases and to University of California, Berkeley for her MPH in Epidemiology. She cared for HIV patients at San Francisco General’s storied Ward 86 clinic and attended on the inpatient ID Consult Service. Prior to joining Gilead, Moupali developed a novel population-based indicator, community viral load (CVL), to evaluate the impact of treatment as prevention. Her CVL research was the basis for measuring CVL and using viral suppression to evaluate the effectiveness of President Barack Obama’s National HIV/AIDS Strategy (NHAS). She served on the Institute of Medicine Committee on Data Systems for Monitoring HIV/AIDS care. She has authored >60 manuscripts, been invited to speak at scientific conferences, policy forums, and for community and advocacy organizations. Her publications were highly cited and garnered significant press coverage including in The New York Times and Nature.
Moupali is committed to ensuring that populations historically underrepresented in HIV clinical trials, such as transgender and gender non-binary people and people of color are meaningfully and intentially included in clinical trials.
Disclosure information not submitted.
Wednesday, March 16, 2022
4:15 PM – 5:15 PM ET
.png)